IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v17y2020i23p8891-d453554.html
   My bibliography  Save this article

Antiviral Agents for the Prevention and Treatment of Herpes Simplex Virus Type-1 Infection in Clinical Oncology: A Network Meta-Analysis

Author

Listed:
  • Farah Wasim Aribi Al-Zoobaee

    (School of Postgraduate Studies, International Medical University, Kuala Lumpur 57000, Malaysia)

  • Loo Yee Shen

    (School of Pharmacy, International Medical University, Kuala Lumpur 57000, Malaysia)

  • Sajesh K. Veettil

    (Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT 84132, USA)

  • Divya Gopinath

    (Oral Diagnostics and Surgical Sciences, School of Dentistry, International Medical University, Kuala Lumpur 57000, Malaysia)

  • Mari Kannan Maharajan

    (Department of Pharmacy Practice, School of Pharmacy, International Medical University, Kuala Lumpur, 57000, Malaysia)

  • Rohit Kunnath Menon

    (Division of Clinical Dentistry, School of Dentistry, International Medical University, Kuala Lumpur 57000, Malaysia)

Abstract

Cancer therapy may be complicated and compromised by viral infections, including oral herpes simplex virus (HSV) infection. This network meta-analysis aimed to identify the best antiviral agent to prevent or treat oral HSV infection in patients being treated for cancer. A search was conducted for trials published since inception until the 10th of May 2020 in MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials. A network meta-analysis was performed on the data from randomized controlled trials that assessed antiviral agents for preventive or therapeutic activity vs. placebo, no treatment or any other active intervention in patients being treated for cancer. The agents were ranked according to their effectiveness in the prevention of oral HSV using surface under the cumulative ranking (SUCRA). Grading of Recommendations, Assessment, Development and Evaluations (GRADE) was used to assess the certainty of the evidence. In total, 16 articles were included. The pooled relative risk (RR) to develop oral HSV infection in the acyclovir group was 0.17 (95% CI: 0.10, 0.30), compared to 0.22 (95% CI: 0.06, 0.77) in the valacyclovir group. Acyclovir ranked highest for the prevention of oral HSV followed by valacyclovir. Subgroup analysis with different acyclovir regimens revealed that the best regimens in terms of HSV-1 prevention were 750 mg/m 2 acyclovir administered intravenously followed by 1600 mg per day orally. Acyclovir (250 mg/m 2 per day) administered intravenously was the least effective against the prevention of oral HSV.

Suggested Citation

  • Farah Wasim Aribi Al-Zoobaee & Loo Yee Shen & Sajesh K. Veettil & Divya Gopinath & Mari Kannan Maharajan & Rohit Kunnath Menon, 2020. "Antiviral Agents for the Prevention and Treatment of Herpes Simplex Virus Type-1 Infection in Clinical Oncology: A Network Meta-Analysis," IJERPH, MDPI, vol. 17(23), pages 1-25, November.
    • Handle: RePEc:gam:jijerp:v:17:y:2020:i:23:p:8891-:d:453554
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/17/23/8891/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/17/23/8891/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Zafar Zafari & Kristian Thorlund & J. FitzGerald & Carlo Marra & Mohsen Sadatsafavi, 2014. "Network vs. Pairwise Meta-Analyses: A Case Study of the Impact of an Evidence-Synthesis Paradigm on Value of Information Outcomes," PharmacoEconomics, Springer, vol. 32(10), pages 995-1004, October.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.

      Corrections

      All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:17:y:2020:i:23:p:8891-:d:453554. See general information about how to correct material in RePEc.

      If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

      If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

      If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

      For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

      Please note that corrections may take a couple of weeks to filter through the various RePEc services.

      IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.